168 related articles for article (PubMed ID: 2878941)
1. Basic pharmacokinetics of bisoprolol, a new highly beta 1-selective adrenoceptor antagonist.
Leopold G; Pabst J; Ungethüm W; Bühring KU
J Clin Pharmacol; 1986; 26(8):616-21. PubMed ID: 2878941
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease.
Kirch W; Rose I; Demers HG; Leopold G; Pabst J; Ohnhaus EE
Clin Pharmacokinet; 1987 Aug; 13(2):110-7. PubMed ID: 2887325
[TBL] [Abstract][Full Text] [Related]
3. Balanced pharmacokinetics and metabolism of bisoprolol.
Leopold G
J Cardiovasc Pharmacol; 1986; 8 Suppl 11():S16-20. PubMed ID: 2439789
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and metabolism of bisoprolol-14C in three animal species and in humans.
Bühring KU; Sailer H; Faro HP; Leopold G; Pabst J; Garbe A
J Cardiovasc Pharmacol; 1986; 8 Suppl 11():S21-8. PubMed ID: 2439794
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the pharmacokinetic properties of bisoprolol and carvedilol in healthy dogs.
Beddies G; Fox PR; Papich MD; Kanikanti VR; Krebber R; Keene BW
Am J Vet Res; 2008 Dec; 69(12):1659-63. PubMed ID: 19046015
[TBL] [Abstract][Full Text] [Related]
6. High beta 1-selectivity and favourable pharmacokinetics as the outstanding properties of bisoprolol.
Haeusler G; Schliep HJ; Schelling P; Becker KH; Klockow M; Minck KO; Enenkel HJ; Schulze E; Bergmann R; Schmitges CJ
J Cardiovasc Pharmacol; 1986; 8 Suppl 11():S2-15. PubMed ID: 2439793
[TBL] [Abstract][Full Text] [Related]
7. Metabolic studies in patients with nadolol: oral and intravenous administration.
Dreyfuss J; Brannick LJ; Vukovich RA; Shaw JM; Willard DA
J Clin Pharmacol; 1977; 17(5-6):300-7. PubMed ID: 16040
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of a single intravenous and oral dose of pafenolol--a beta 1-adrenoceptor antagonist with atypical absorption and disposition properties--in man.
Regårdh CG; Lundborg P; Gabrielsson M; Heggelund A; Kylberg-Hanssen K
Pharm Res; 1990 Dec; 7(12):1222-7. PubMed ID: 1982773
[TBL] [Abstract][Full Text] [Related]
9. [The pharmacokinetics of 1-(4-cyclohexylureidophenoxy)-2-hydroxy-3-tert-butylaminopropane (talinolol, Cordanum, 02-115) 2. Excretion, blood level and distribution of the 14C-labeled compound in the rat].
Klemm W; Wenzel A
Pharmazie; 1975 Oct; 30(10):675-7. PubMed ID: 695
[No Abstract] [Full Text] [Related]
10. Pharmacokinetics and absolute bioavailability of carteolol, a new beta-adrenergic receptor blocking agent.
Ishizaki T; Ohnishi A; Sasaki T; Kushida K; Horai Y; Chiba K; Suganuma T
Eur J Clin Pharmacol; 1983; 25(1):95-101. PubMed ID: 6137389
[TBL] [Abstract][Full Text] [Related]
11. Reduction of exercise tachycardia in man after propranolol, atenolol and bisoprolol in comparison to beta-adrenoceptor occupancy.
Wellstein A; Palm D; Belz GG; Butzer R; Polsak R; Pett B
Eur Heart J; 1987 Dec; 8 Suppl M():3-8. PubMed ID: 2897299
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of betaxolol in middle aged patients.
Bianchetti G; Thiercelin JF; Thenot JP
Eur J Clin Pharmacol; 1986; 31(2):231-3. PubMed ID: 2879735
[TBL] [Abstract][Full Text] [Related]
13. Concentration kinetics of propranolol, bisoprolol, and atenolol in humans assessed with chemical detection and a subtype-selective beta-adrenoceptor assay.
Wellstein A; Palm D; Belz GG; Leopold G; Bühring KU; Pabst J
J Cardiovasc Pharmacol; 1986; 8 Suppl 11():S41-5. PubMed ID: 2439797
[TBL] [Abstract][Full Text] [Related]
14. The single dose pharmacokinetics of bisoprolol (10 mg) in renal insufficiency: the clinical significance of balanced clearance.
Payton CD; Fox JG; Pauleau NF; Boulton-Jones JM; Ioannides C; Johnston A; Thomas P
Eur Heart J; 1987 Dec; 8 Suppl M():15-22. PubMed ID: 2897297
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacokinetics and metabolism of bevantolol.
Latts JR
Angiology; 1986 Mar; 37(3 Pt 2):221-5. PubMed ID: 2871781
[TBL] [Abstract][Full Text] [Related]
16. Interaction of bisoprolol with cimetidine and rifampicin.
Kirch W; Rose I; Klingmann I; Pabst J; Ohnhaus EE
Eur J Clin Pharmacol; 1986; 31(1):59-62. PubMed ID: 2877885
[TBL] [Abstract][Full Text] [Related]
17. Disposition and bioavailability of the beta 1-adrenoceptor antagonist talinolol in man.
Trausch B; Oertel R; Richter K; Gramatté T
Biopharm Drug Dispos; 1995 Jul; 16(5):403-14. PubMed ID: 8527689
[TBL] [Abstract][Full Text] [Related]
18. Stereoselective pharmacokinetics of bisoprolol after intravenous and oral administration in beagle dogs.
Horikiri Y; Suzuki T; Mizobe M
J Pharm Sci; 1997 May; 86(5):560-4. PubMed ID: 9145379
[TBL] [Abstract][Full Text] [Related]
19. Absolute bioavailability study in the dog with Visacor, a new cardioselective beta blocking drug with intrinsic sympathomimetic activity.
McAinsh J; Smith RP; Ferguson RA
Eur J Drug Metab Pharmacokinet; 1984; 9(2):129-39. PubMed ID: 6146530
[TBL] [Abstract][Full Text] [Related]
20. Effects of a meal and its composition on the bioavailability of betaxolol administered orally to healthy subjects.
Thiercelin JF; Bianchetti G; Larribaud J; Ganansia J; Deves C; Trocherie S; Abriol C; Morselli PL
World Rev Nutr Diet; 1984; 43():183-6. PubMed ID: 6147938
[No Abstract] [Full Text] [Related]
[Next] [New Search]
